Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Verastem Oncology is seeking a Lead Clinical Pharmacology and MIDD professional to guide small molecule oncology programs from first-in-human studies through registration. The role integrates nonclinical, translational, and clinical data to optimize dose, regimen, and regulatory decisions.
You will supervise PK/PD studies, biomarker workups, and biomarker-driven dosing strategies while collaborating with pharmacometricians on modeling and simulation.
At Verastem Oncology, we address urgent needs of patients living with cancers driven by RAS/MAPK pathway mutations, a key driver of tumor growth and treatment resistance. FDA approval of AVMAPKI FAKZYNJA CO-PACK delivered the first therapy for women living with recurrent KRAS-mutated low-grade serous ovarian cancer, a rare cancer with significant unmet need. We've launched this novel/novel combination therapy in the U.S. and are exploring pathways for Europe and Japan. We continue to advance our pipeline of drugs to help block cancer cell survival, inhibit tumor growth, and overcome treatment resistance. This is an exciting opportunity to shape the future of cancer care and make a meaningful impact in the lives of patients.
Lead clinical pharmacology and model informed drug development (MIDD) for small molecule oncology programs from first-in-human studies through registration. Integrate nonclinical, translational, and clinical evidence to guide study design, dose and regimen optimization, and regulatory decisions. This role owns clinical pharmacology strategy and study support, partnering closely with pharmacometricians on modeling and simulation. The position is expected to align primarily with Director or Senior Director scope; experienced Associate Director candidates will be considered.